[{"status":"ok","data":{"results":[{"id":168772,"title":"Fan maker Volution to extract \u00a3100m from IPO","type":"article","status":"live","url":"http:\/\/www.ft.com\/fastft?post=168772","shorturl":"http:\/\/on.ft.com\/1iFLDI8\n","content":"<p>Volution, the latest property related business to take advantage of Britain's frothy housing market, has priced its London IPO, valuing the business at \u00a3300m. <\/p>\n\n<p>The ventilation product maker's IPO is expected to raise \u00a3100m for the company and selling shareholders, including its private equity backer TowerBrook Capital. <\/p>\n\n<p>Volution is one of a flurry of construction related companies to have tapped the equity markets recently, including listing website <a href=\"http:\/\/on.ft.com\/1pfKRY8\">Zoopla<\/a> and plastic pipe supplier Polypipe. <\/p>\n\n<p>It may also be hoping to attract some patriotic investors too, after winning praise from David Cameron for <a href=\"http:\/\/www.vent-axia.com\/news\/latest-news\/british-manufacturer-vent-axia-welcomes-prime-minister-david-cameron-24-jan-2014.htm\">bringing some manufacturing back<\/a> to Britain from China. <\/p>\n\n<p>In the year to the end of July, Volution had revenues of \u00a3102m \u2013 up about 14 per cent on the prior year \u2013 and adjusted earnings before interest, tax, depreciation and amortisation of \u00a324m, a rise of 10 per cent.<\/p>\n\n<p>The company will make its market debut with a stock price of 150p per share, it said in a statement, with dealing to commence on June 23. <\/p>\n\n<p>On admission, TowerBrook will be interested in approximately 61.4 per cent of the company's shares, which are subject to a 180 day lock-up.<\/p>\n\n<p>\u00b7<\/p>","abstract":"<p>Volution, the latest property related business to take advantage of Britain's frothy housing market, has priced its London IPO, valuing the business at \u00a3300m.<\/p>","datepublished":"1403074606","authorpseudonym":"Naomi Rovnick","currentrevision":4578102,"attachments":[],"metadata":{"primarytagid":"113002"},"issticky":false,"tags":[{"tag":"Companies","id":113002,"tagid":113002,"tx":"Sector","txprefix":"sector","txid":4010,"query":"sector:Companies","classname":"blue-2"},{"tag":"Volution","id":129862,"tagid":129862,"tx":"Company","txprefix":"company","txid":4050,"query":"company:Volution","classname":null}],"uuidv3":"c89a64a0-9af1-37f4-9fef-df9116144e47","sortval":"0-0-01403074606"},{"id":162502,"title":"Juncker 'confident' of EC presidency","type":"article","status":"live","url":"http:\/\/www.ft.com\/fastft?post=162502","shorturl":"http:\/\/on.ft.com\/1kKg2od\n","content":"<p>Jean-Claude Juncker appears to be (very) sure that he will be the next president of the European Commission, despite fierce opposition from UK premier David Cameron.<\/p>\n\n<p>So confident, in fact, that he <a href=\"https:\/\/twitter.com\/JunckerEU\/status\/474114809462816768\">tweeted the following today<\/a>.<\/p>\n\n<blockquote>\n  <p>I am more confident than ever that I will be the next European Commission President.<\/p>\n<\/blockquote>\n\n<p><a href=\"http:\/\/www.ft.com\/cms\/s\/0\/ed89deea-e657-11e3-9a20-00144feabdc0.html\">Other candidates<\/a> have included Finland's Jyrki Katainen, Poland's Donald Tusk and even the International Monetary Fund's Christine Lagarde. Mr Cameron has led the fight against Mr Juncker, but he appears to be heading towards another chastening European defeat. <\/p>\n\n<p><a href=\"http:\/\/www.ft.com\/cms\/s\/0\/621d823e-eb2b-11e3-9c8b-00144feabdc0.html?siteedition=uk\">From the overnight FT story:<\/a><\/p>\n\n<blockquote>\n  <p>\u2026In parts of Brussels and Berlin attitudes towards Britain are hardening; Mr Juncker believes momentum is building in his favour and British officials privately concede the diplomatic mood is becoming sour.<\/p>\n  \n  <p>Mr Juncker was the lead candidate of the centre-right European People's party, which won the most seats in the European elections and claims he has a democratic mandate to head the EU executive.<\/p>\n<\/blockquote>","abstract":"<p>Jean-Claude Juncker appears to be (very) sure that he will be the next president of the European Commission, despite fierce opposition from UK premier David Cameron.<\/p>","datepublished":"1401880102","authorpseudonym":"Robin Wigglesworth","currentrevision":4455152,"attachments":[{"id":95302,"postid":162502,"userid":24502,"title":"Capture(2).PNG","path":"\/2014-06\/04\/Capture(2).PNG","mimetype":"image\/png","size":11955,"content":"<div class='formatted-img' data-src='http:\/\/clamo.ftdata.co.uk\/files\/2014-06\/04\/Capture%282%29.PNG'><\/div>"}],"metadata":{"primarytagid":"113072"},"issticky":false,"tags":[{"tag":"EU","id":86092,"tagid":86092,"tx":"Topic","txprefix":"topic","txid":4000,"query":"topic:EU","classname":null},{"tag":"Jean-Claude Juncker","id":89902,"tagid":89902,"tx":"Person","txprefix":"person","txid":4020,"query":"person:\"Jean-Claude Juncker\"","classname":null},{"tag":"European Commission","id":100252,"tagid":100252,"tx":"Institution","txprefix":"institution","txid":4040,"query":"institution:\"European Commission\"","classname":null},{"tag":"World News","id":113072,"tagid":113072,"tx":"Topic","txprefix":"topic","txid":4000,"query":"topic:\"World News\"","classname":"turquoise"}],"uuidv3":"ce3ee27b-dd58-3a23-9284-56ea5b23f64b","sortval":"0-0-01401880102"},{"id":162352,"title":"Monitise appoints co-CEO","type":"article","status":"live","url":"http:\/\/www.ft.com\/fastft?post=162352","shorturl":"http:\/\/on.ft.com\/1kJmWKC\n","content":"<p>Mobile payments tech company Monitise is cashing in on the extra expertise that a co-chief executive can provide, naming a former Visa payments executive to the new role.<\/p>\n\n<p>The London-listed company said Elizabeth Buse would begin working alongside Monitise founder and current CEO Alastair Lukies with immediate effect.<\/p>\n\n<p>Lee Cameron continues his role as deputy chief executive and Chief Commercial Officer.<\/p>\n\n<p><a href=\"http:\/\/www.investegate.co.uk\/monitise-plc--moni-\/rns\/monitise-announces-board-appointments\/201406040700097743I\/\">Monitise said of the unusual management change:<\/a><\/p>\n\n<blockquote>\n  <p>Elizabeth, an American national who was a member of the Monitise Board from July 2010 to October 2012, will head Monitise's day-to-day operations, overseeing technology, product, sales and marketing while Alastair focuses on key relationships with partners and industry stakeholders, corporate development and major shareholders.<\/p>\n<\/blockquote>\n\n<p>Monitise set itself a \"Mobile Money\" growth target this year of increasing its registered users from 28m to 200m by the end of its 2018 fiscal year and growing revenues from users through mobile banking, payments and commerce.<\/p>\n\n<p>Elizabeth Buse said: <\/p>\n\n<blockquote>\n  <p>Monitise occupies a unique position in the global Mobile Money ecosystem as one of the few technology enablers with proven bank-grade solutions across banking, payments and commerce. I cannot see a better-placed business to take advantage of the Mobile Money opportunity and am delighted to be joining Monitise. <\/p>\n<\/blockquote>\n\n<p>Monitise also announced it had appointed two new independent non-executive directors: Amanda Burton and Paulette Garafalo,<\/p>","abstract":"<p>Mobile payments tech company Monitise is cashing in on the extra expertise that a co-chief executive can provide, naming a former Visa payments executive to the new role.<\/p>","datepublished":"1401865177","authorpseudonym":"Chris Nuttall","currentrevision":4451822,"attachments":[],"metadata":{"primarytagid":"113002"},"issticky":false,"tags":[{"tag":"UK","id":98232,"tagid":98232,"tx":"Location","txprefix":"location","txid":4030,"query":"location:UK","classname":null},{"tag":"Companies","id":113002,"tagid":113002,"tx":"Sector","txprefix":"sector","txid":4010,"query":"sector:Companies","classname":"blue-2"},{"tag":"Banking","id":113112,"tagid":113112,"tx":"Sector","txprefix":"sector","txid":4010,"query":"sector:Banking","classname":null},{"tag":"Monitise","id":129092,"tagid":129092,"tx":"Company","txprefix":"company","txid":4050,"query":"company:Monitise","classname":null}],"uuidv3":"6a7624b6-b181-3ff2-8ffd-98869fab6b65","sortval":"0-0-01401865177"},{"id":160302,"title":"Lend Lease wins UK \"super-prison\" contract","type":"article","status":"live","url":"http:\/\/www.ft.com\/fastft?post=160302","shorturl":"http:\/\/on.ft.com\/1o4eqtl\n","content":"<p>Lend Lease, the Australian developer, has won a \u00a3151m contract to build the UK's first super-prison housing over 2,000 inmates in Wrexham, north Wales. <\/p>\n\n<p>The property company, which built Kent's Bluewater shopping centre, will transform the former site of a Firestone tyre factory in time for the jail opening in late 2017, as <strong>the FT's Helen Warrell reports.<\/strong> <\/p>\n\n<p>The prison comprises a vast complex of three sleeping wings and two skills workshops. Additional buildings will provide space for visitors, education facilities and a \"faith centre\".<\/p>\n\n<p>Despite government estimates that the super-structure will contribute \u00a323m a year to the local economy, Labour and Plaid Cymru have both opposed the new prison. <\/p>\n\n<p>The former Labour government eventually abandoned its plans for large, US-style \"titan\" prisons, following criticism from justice charities that large prison \"warehouses\" were impersonal and difficult to manage.<\/p>\n\n<p>The debate has sparked embarrassment for David Cameron, who famously said in opposition that \"the idea that big is beautiful with prisons is wrong'. <\/p>\n\n<p>Further concerns have been raised about the size of the new jail after riots this year at HMP Oakwood, one of the UK's largest prisons, which has just over 1,600 inmates.<\/p>\n\n<p>However Jeremy Wright, prisons minister, denied that the prison would be a \"monolithic residential block with 2,000 people in it\".<\/p>\n\n<p>\"Contrary to public belief we're not interested in creating one big warehouse for prisoners,\" he told the Financial Times. \"It's quite important that you break it down so the residential units are smaller, they're more manageable when they're smaller but you get the economies of scale you need in order to provide good central facilities.\"<\/p>","abstract":"<p>Lend Lease, the Australian developer, has won a \u00a3151m contract to build the UK's first super-prison housing over 2,000 inmates in Wrexham, north Wales.<\/p>","datepublished":"1401438603","authorpseudonym":"Megan Murphy","currentrevision":4413912,"attachments":[],"metadata":{"primarytagid":"113002"},"issticky":false,"tags":[{"tag":"UK","id":98232,"tagid":98232,"tx":"Location","txprefix":"location","txid":4030,"query":"location:UK","classname":null},{"tag":"England and Wales","id":99712,"tagid":99712,"tx":"Location","txprefix":"location","txid":4030,"query":"location:\"England and Wales\"","classname":null},{"tag":"Lend Lease","id":102622,"tagid":102622,"tx":"Company","txprefix":"company","txid":4050,"query":"company:\"Lend Lease\"","classname":null},{"tag":"Companies","id":113002,"tagid":113002,"tx":"Sector","txprefix":"sector","txid":4010,"query":"sector:Companies","classname":"blue-2"}],"uuidv3":"28be20ab-f563-356d-b8f2-f52916c89e87","sortval":"0-0-01401438603"},{"id":155552,"title":"UK house price growth cools in March - ONS","type":"article","status":"live","url":"http:\/\/www.ft.com\/fastft?post=155552","shorturl":"http:\/\/on.ft.com\/1nhglua\n","content":"<p>Growth in UK house prices has cooled a little, with the increase of 8 per cent in the year to March down from 9.2 per cent in February.<\/p>\n\n<p><a href=\"http:\/\/www.ons.gov.uk\/ons\/rel\/hpi\/house-price-index\/march-2014\/index.html\">The Office for National Statistics report<\/a> said house prices continued to increase strongly across most parts of the UK, with prices in London (up 17.0 per cent) again showing the highest growth.<\/p>\n\n<p>House price annual inflation was 8.5 per cent in England, 4.9 per cent in Wales, 0.8 per cent in Scotland and 0.3 per cent in Northern Ireland.<\/p>\n\n<p>Excluding London and the South East, UK house prices increased by 4.7 per cent in the 12 months to March 2014.<\/p>\n\n<p>On a seasonally adjusted basis, average house prices fell by 0.5 per cent between February and March 2014.<\/p>\n\n<p>Speaking on Radio 4's <em>Today<\/em> programme this morning, the UK prime minister David Cameron said <a href=\"http:\/\/www.ft.com\/cms\/s\/0\/89d7eea2-dff2-11e3-b709-00144feabdc0.html\">he would consider any changes to the government's Help To Buy scheme<\/a> suggested by the Bank of England. The scheme is designed to help first-time buyers, but has been blamed by critics for contributing to an overheating of the market. Mr Cameron said the government was prepared to look at reducing the programme's current threshold of \u00a3600,000.<\/p>\n\n<p>Here's the ONS bar chart for March and rates graph since 2004:<\/p>","abstract":"<p>Growth in UK house prices has cooled a little, with the increase of 8 per cent in the year to March down from 9.2 per cent in February.<\/p>","datepublished":"1400575139","authorpseudonym":"Chris Nuttall","currentrevision":4317692,"attachments":[{"id":91112,"postid":155552,"userid":24432,"title":"housemarch.PNG","path":"\/2014-05\/20\/housemarch.PNG","mimetype":"image\/png","size":72973,"content":"<div class='formatted-img' data-src='http:\/\/clamo.ftdata.co.uk\/files\/2014-05\/20\/housemarch.PNG'><\/div>"},{"id":91122,"postid":155552,"userid":24432,"title":"housemarch2.PNG","path":"\/2014-05\/20\/housemarch2.PNG","mimetype":"image\/png","size":80466,"content":"<div class='formatted-img' data-src='http:\/\/clamo.ftdata.co.uk\/files\/2014-05\/20\/housemarch2.PNG'><\/div>"}],"metadata":{"primarytagid":"86032"},"issticky":false,"tags":[{"tag":"Economy","id":86032,"tagid":86032,"tx":"Topic","txprefix":"topic","txid":4000,"query":"topic:Economy","classname":"red-2"},{"tag":"UK house prices","id":87872,"tagid":87872,"tx":"Topic","txprefix":"topic","txid":4000,"query":"topic:\"UK house prices\"","classname":null},{"tag":"Office for National Statistics","id":116143,"tagid":116143,"tx":"Institution","txprefix":"institution","txid":4040,"query":"institution:\"Office for National Statistics\"","classname":null}],"uuidv3":"18d8f6aa-1672-376f-9bc7-c999532d4eb6","sortval":"0-0-01400575139"},{"id":152892,"title":"Miliband slams Cameron's Pfizer stance","type":"article","status":"live","url":"http:\/\/www.ft.com\/fastft?post=152892","shorturl":"http:\/\/on.ft.com\/1mqpjqB\n","content":"<p>Ed Miliband has used this week's session of prime minister's questions once more to criticise David Cameron over his stance on the proposed takeover of AstraZeneca by Pfizer.<\/p>\n\n<p>The Labour leader has taken a tough stance against the Pfizer bid, telling the Commons the company's assurances over jobs and research and development are \"worthless\".<\/p>\n\n<p>Interestingly, the Labour leader met Ian Read, Pfizer's chief executive on Tuesday, a meeting that his advisers called \"business-like and useful\". <\/p>\n\n<p>But if Mr Read intended to use the meeting to soften Labour's line on the deal, it backfired. Opposition officials said Mr Miliband left the meeting even more convinced that a public interest test was necessary. <\/p>\n\n<p>They said Mr Miliband's debrief following the private session started with the words: \"The case for a public interest test is now overwhelming.\"<\/p>","abstract":"<p>Ed Miliband has used this week's session of prime minister's questions once more to criticise David Cameron over his stance on the proposed takeover of AstraZeneca by Pfizer.<\/p>","datepublished":"1400070216","authorpseudonym":"Robin Wigglesworth","currentrevision":4258742,"attachments":[],"metadata":{"primarytagid":"113072"},"issticky":false,"tags":[{"tag":"Pharmaceuticals","id":88612,"tagid":88612,"tx":"Sector","txprefix":"sector","txid":4010,"query":"sector:Pharmaceuticals","classname":null},{"tag":"UK","id":98232,"tagid":98232,"tx":"Location","txprefix":"location","txid":4030,"query":"location:UK","classname":null},{"tag":"Pfizer","id":102192,"tagid":102192,"tx":"Company","txprefix":"company","txid":4050,"query":"company:Pfizer","classname":null},{"tag":"AstraZeneca","id":102332,"tagid":102332,"tx":"Company","txprefix":"company","txid":4050,"query":"company:AstraZeneca","classname":null},{"tag":"World News","id":113072,"tagid":113072,"tx":"Topic","txprefix":"topic","txid":4000,"query":"topic:\"World News\"","classname":"turquoise"}],"uuidv3":"382ee784-5986-312b-be07-3673ef0cb2da","sortval":"0-0-01400070216"},{"id":152832,"title":"UK PM resists calls for Pfizer intervention","type":"article","status":"live","url":"http:\/\/www.ft.com\/fastft?post=152832","shorturl":"http:\/\/on.ft.com\/1mqbDeZ\n","content":"<p>The British prime minister David Cameron has resisted calls from the Labour opposition that the government should intervene in Pfizer's bid to acquire UK-based AstraZeneca.<\/p>\n\n<p>Speaking at Prime Minister's Questions, Ed Miliband, the Labour leader, said the government should block the deal if it failed a test of being in the public interest. He accused the prime minister of not intervening because he was \"falling back on the old idea that the market always knows best and doesn't need rules\".<\/p>\n\n<p>Mr Cameron said overseas companies were attracted to Britain because of its open economy, with 175,000 people employed in life sciences in the UK and companies such as Eli Lilly, Johnson &amp; Johnson and Novartis choosing to invest in the UK because it was a great place to do business. He said:<\/p>\n\n<blockquote>\n  <p>We measure the British interest in British jobs, British science and British investment, but we also measure it on being a country that is open to overseas investment.<\/p>\n<\/blockquote>\n\n<p>Asked by Mr Miliband on what assurances the government could extract from Pfizer, regarding preserving jobs, not cutting research and avoiding a breakup of AstraZeneca, Mr Cameron said the government wanted the strongest possible guarantees. He added:<\/p>\n\n<blockquote>\n  <p>What we want is a good outcome for British investment and British jobs. We have assurances on the percentage of R&amp;D that will happen here, on investment in Cambridge, on investment in Macclesfield, if he's arguing do we want further assurances, yes we do. Do we want to make sure those jobs stay here? Yes we do. Do we want more investment in British universities and British science? Yes we do.<\/p>\n<\/blockquote>\n\n<p>MPs have been grilling executives involved in the proposed \u00a363bn takeover for a second day and <a href=\"http:\/\/www.ft.com\/cms\/s\/0\/4b0a73d6-db45-11e3-94ad-00144feabdc0.html\">Andrew Jack's report is here<\/a>. <\/p>","abstract":"<p>The British prime minister David Cameron has resisted calls from the Labour opposition that the government should intervene in Pfizer's bid to acquire UK-based AstraZeneca.<\/p>","datepublished":"1400068094","authorpseudonym":"Chris Nuttall","currentrevision":4258102,"attachments":[],"metadata":{"primarytagid":"113072"},"issticky":false,"tags":[{"tag":"David Cameron","id":88992,"tagid":88992,"tx":"Person","txprefix":"person","txid":4020,"query":"person:\"David Cameron\"","classname":null},{"tag":"Ed Miliband","id":89492,"tagid":89492,"tx":"Person","txprefix":"person","txid":4020,"query":"person:\"Ed Miliband\"","classname":null},{"tag":"UK","id":98232,"tagid":98232,"tx":"Location","txprefix":"location","txid":4030,"query":"location:UK","classname":null},{"tag":"World News","id":113072,"tagid":113072,"tx":"Topic","txprefix":"topic","txid":4000,"query":"topic:\"World News\"","classname":"turquoise"}],"uuidv3":"3670b134-e6f6-3556-8432-c68926271ce6","sortval":"0-0-01400068094"},{"id":151962,"title":"Pfizer CEO faces UK MPs: live blog","type":"article","status":"live","url":"http:\/\/www.ft.com\/fastft?post=151962","shorturl":"http:\/\/on.ft.com\/1mkxRPK\n","content":"<p>Pfizer chief executive Ian Read will face UK lawmakers today from 10am, an important moment in the mammoth \u00a363bn (for now) bid for AstraZeneca.<\/p>\n\n<p>The FT's newsdesk is live-blogging the hearing <a href=\"http:\/\/blogs.ft.com\/westminster\/liveblogs\/2014-05-13-2\/\">here<\/a> but here is a <a href=\"http:\/\/www.ft.com\/cms\/s\/0\/597b9cac-d793-11e3-80e0-00144feabdc0.html\">Q&amp;A from Saturday<\/a> by our pharmaceuticals correspondent, Andrew Ward, on what could be a pivotal week for the two companies. <\/p>\n\n<p>From the Q&amp;A:<\/p>\n\n<p><strong>Could politics derail the deal?<\/strong><\/p>\n\n<blockquote>\n  <p>While UK prime minister David Cameron has floated the possibility of expanding government powers to apply a public interest test, ministers admit this option would only be taken \"in extremis\". Instead, Downing Street is focused on trying to secure more commitments from Pfizer on jobs.\n  The US company says it is hard to make further promises without talking to AstraZeneca about how a deal would work. Much could rest on next week's parliamentary hearings. If Mr Read gets a mauling, politics may start to cast a darker cloud. <\/p>\n  \n  <p>Across the Atlantic, meanwhile, two prominent Democratic senators have vowed to push for legislation to make it harder for multinationals such as Pfizer to redomicile overseas to escape US taxes. So far, however, there is little sign of the Republican backing that would be needed for such a law to be passed quickly enough to imperil the deal.<\/p>\n<\/blockquote>\n\n<p>In addition to Mr Read, Pascal Soriot, the CEO of AstraZeneca, and UK business minister Vince Cable, among others, will also be testifying to the parliamentary committee.<\/p>","abstract":"<p>Pfizer chief executive Ian Read will face UK lawmakers today from 10am, an important moment in the mammoth \u00a363bn (for now) bid for AstraZeneca.<\/p>","datepublished":"1399966860","authorpseudonym":"Robin Wigglesworth","currentrevision":4241642,"attachments":[],"metadata":{"primarytagid":"113002"},"issticky":false,"tags":[{"tag":"Pharmaceuticals","id":88612,"tagid":88612,"tx":"Sector","txprefix":"sector","txid":4010,"query":"sector:Pharmaceuticals","classname":null},{"tag":"Pfizer","id":102192,"tagid":102192,"tx":"Company","txprefix":"company","txid":4050,"query":"company:Pfizer","classname":null},{"tag":"AstraZeneca","id":102332,"tagid":102332,"tx":"Company","txprefix":"company","txid":4050,"query":"company:AstraZeneca","classname":null},{"tag":"Companies","id":113002,"tagid":113002,"tx":"Sector","txprefix":"sector","txid":4010,"query":"sector:Companies","classname":"blue-2"}],"uuidv3":"7ab0bcc5-2d14-3dc6-8e0a-c32fa4950e04","sortval":"0-0-01399966860"},{"id":151292,"title":"Pfizer: UK commitments are legally binding","type":"article","status":"live","url":"http:\/\/www.ft.com\/fastft?post=151292","shorturl":"http:\/\/on.ft.com\/1mQQMzP\n","content":"<p>Ahead of its chief executive getting quizzed by UK MPs over its proposed \u00a363bn takeover of AstraZeneca, Pfizer has released the full text of a letter sent to the UK's Business, Innovation and Skills Committee.before tomorrow's session. <\/p>\n\n<p>The US drugs giant, which is seeking to head off formal political intervention in the bid, stressed that it considered the list of commitments it made to maintaining AstraZeneca's commitment to the UK earlier this month would be binding under UK law. <\/p>\n\n<p>From the memorandum: <\/p>\n\n<blockquote>\n  <p>Subject to\n  successful completion of our combination with AstraZeneca, on the basis proposed by us, we will\n  make the following series of significant and tangible commitments:<\/p>\n  \n  <p>\u2022 We will establish the combined company's corporate and tax residence in England<\/p>\n  \n  <p>\u2022 AstraZeneca's substantial R&amp;D innovation hub in Cambridge will be completed<\/p>\n  \n  <p>\u2022 Key scientific leadership will be located in the UK<\/p>\n  \n  <p>\u2022 20% of the combined company's total R&amp;D workforce will be located in the UK going\n  forward<\/p>\n  \n  <p>\u2022 We will retain substantial commercial manufacturing facilities at Macclesfield<\/p>\n  \n  <p>\u2022 We will locate the European Business Headquarters and European Regulatory Headquarters\n  in the UK<\/p>\n  \n  <p>\u2022 At least two AstraZeneca Board Members will be invited to join the combined company's board<\/p>\n  \n  <p>\u2022 Board meetings for the new company would be held in the UK as appropriate and the new\n  company would be committed to meaningful participation in the UK commercial, economic\n  and social community\n  ... <\/p>\n  \n  <p>To ensure our commitments are binding, we included them with our proposed offer\n  announcement understanding fully that they would be binding as a matter of English law.<\/p>\n  \n  <p>Under the current version of the UK Takeover Code, any statement of a particular course of\n  action we intend to take, or not take, will give rise to a commitment by which we will be bound\n  under the Code.<\/p>\n  \n  <p>That is why, recognising the force of the new Code rules, the commitments made in\n  our letter to the Prime Minister on 2 May should be given full weight<\/p>\n<\/blockquote>\n\n<p>Pfizer chief executive Ian Read and AstraZeneca chief Pascal Soriot will both face off with members of the committee tomorrow in London. <\/p>\n\n<p>UK Prime Minister David Cameron and other ministers have in recent days said they are pressing Pfizer for more cast-iron commitments on jobs and investment.<\/p>\n\n<p>However, Pfizer has said it cannot make further promises without first talking to AstraZeneca about how a deal would work. The UK company has so far refused to sit down with its US suitor, dismissing its \u00a350 a share proposal as a \"significant undervaluation\".<\/p>\n\n<p>Mr Read is expected to face tough questioning from MPs amid calls from the opposition Labour party for the proposed deal to be subjected to a \"public interest test\".<\/p>\n\n<p>In its memo to MPs on Monday, Pfizer said a tie-up with AstraZeneca would \"deliver great benefits to the United Kingdom and to patients and science globally\".<\/p>\n\n<p>It highlighted the \"difficult challenges\" faced by AstraZeneca as \"looming patent expiries and near-term revenue losses jeopardise its ability to deliver\" new drugs.<\/p>\n\n<p>\"By combining our resource, we would bolster each organisation's ability to bring new innovative medicines to patients in need,\" Pfizer said.<\/p>","abstract":"<p>Ahead of its chief executive getting quizzed by UK MPs over its proposed \u00a363bn takeover of AstraZeneca, Pfizer has released the full text of a letter sent to the UK's Business, Innovation and Skills Committee.before tomorrow's session.<\/p>","datepublished":"1399887550","authorpseudonym":"Megan Murphy","currentrevision":4227162,"attachments":[],"metadata":{"primarytagid":"113002"},"issticky":false,"tags":[{"tag":"Pfizer","id":102192,"tagid":102192,"tx":"Company","txprefix":"company","txid":4050,"query":"company:Pfizer","classname":null},{"tag":"AstraZeneca","id":102332,"tagid":102332,"tx":"Company","txprefix":"company","txid":4050,"query":"company:AstraZeneca","classname":null},{"tag":"Companies","id":113002,"tagid":113002,"tx":"Sector","txprefix":"sector","txid":4010,"query":"sector:Companies","classname":"blue-2"}],"uuidv3":"a03e8c81-41d5-379a-9562-62dfef36dfe5","sortval":"0-0-01399887550"},{"id":147622,"title":"Wynn leads casinos higher as Macau shines","type":"article","status":"live","url":"http:\/\/www.ft.com\/fastft?post=147622","shorturl":"http:\/\/on.ft.com\/1i6ubuV\n","content":"<p>Macau, China's offshore gambling centre, is helping shares of casino operators avoid the sideways drift in the wider US stock market.<\/p>\n\n<p>Shares of <a href=\"http:\/\/markets.ft.com\/research\/Markets\/Tearsheets\/Summary?s=WYNN:NSQ\">Wynn Resorts<\/a> led a charge in casino operators on Friday, with a 6 per cent rise. <a href=\"http:\/\/markets.ft.com\/research\/Markets\/Tearsheets\/Summary?s=MGM:NYQ\">MGM Resorts<\/a> climbed 3 per cent and <a href=\"http:\/\/markets.ft.com\/research\/Markets\/Tearsheets\/Summary?s=LVS:NYQ\">Las Vegas Sands<\/a> were 2 per cent stronger.<\/p>\n\n<p>All were buoyed by a jump in gaming revenues last month in Macau, as new rail connections to mainland China make it easier to get there.<\/p>\n\n<p>Revenues rose 11 per cent from a year earlier to 31.1bn patacas, or $3.9bn, the Gaming Inspection and Coordination Bureau said overnight. That topped expectations for a 7 per cent rise.<\/p>\n\n<p>Separately, Wynn said it remained on track to open its latest 1,700 room resort in Macau in the first half of 2016, and both mass market and VIP segments in Macau showed 20 per cent plus growth. <\/p>\n\n<p>Analysts on Wall Street said they expected strong growth to continue, even as a spate of new hotels open.\nCameron McKnight, an analyst at Wells Fargo, said:<\/p>\n\n<blockquote>\n  <p>May Golden Week is off to a very strong start, with record mass market crowds in Macau over the past four days. Even our most sceptical contacts in Macau are surprised at the crowds they've seen this week.<\/p>\n<\/blockquote>\n\n<p>Golden Week is a holiday at the start of May in several Asian companies, including Japan and China.<\/p>","abstract":"<p>Macau, China's offshore gambling centre, is helping shares of casino operators avoid the sideways drift in the wider US stock market.<\/p>","datepublished":"1399052953","authorpseudonym":"Eric Platt","currentrevision":4150032,"attachments":[{"id":87332,"postid":147622,"userid":24302,"title":"http:\/\/markets.ft.com\/RESEARCH\/API\/ChartBuilder?t=equities&p=eyJzeW1ib2wiOiIyODg3Mjd8MTk0NTY3fDIwMDE","path":"http:\/\/markets.ft.com\/RESEARCH\/API\/ChartBuilder?t=equities&p=eyJzeW1ib2wiOiIyODg3Mjd8MTk0NTY3fDIwMDE2MCIsInJlZ2lvbiI6bnVsbCwiaGVpZ2h0IjoiMzM4Iiwid2lkdGgiOiI2MDAiLCJsaW5lU3R5bGUiOiJtb3VudGFpbiIsImR1cmF0aW9uIjoiMzY1Iiwic3RhcnREYXRlIjpudWxsLCJlbmREYXRlIjpudWxsLCJwcmltYXJ5TGFiZWwiOiJXWU5OOk5TUSIsInNlY29uZGFyeUxhYmVsIjoiTFZTOk5ZUSIsInRlcnRpYXJ5TGFiZWwiOiJNR006TllTIiwicXVhdGVybmFyeUxhYmVsIjpudWxsLCJpc01vYmlsZSI6ZmFsc2UsIlNob3dEaXNjbGFpbWVyIjp0cnVlLCJ1bml0IjoicHgifQ==","mimetype":"image\/gif","size":16371,"content":"<div class='formatted-img' data-src='http:\/\/markets.ft.com\/RESEARCH\/API\/ChartBuilder?t=equities&amp;p=eyJzeW1ib2wiOiIyODg3Mjd8MTk0NTY3fDIwMDE2MCIsInJlZ2lvbiI6bnVsbCwiaGVpZ2h0IjoiMzM4Iiwid2lkdGgiOiI2MDAiLCJsaW5lU3R5bGUiOiJtb3VudGFpbiIsImR1cmF0aW9uIjoiMzY1Iiwic3RhcnREYXRlIjpudWxsLCJlbmREYXRlIjpudWxsLCJwcmltYXJ5TGFiZWwiOiJXWU5OOk5TUSIsInNlY29uZGFyeUxhYmVsIjoiTFZTOk5ZUSIsInRlcnRpYXJ5TGFiZWwiOiJNR006TllTIiwicXVhdGVybmFyeUxhYmVsIjpudWxsLCJpc01vYmlsZSI6ZmFsc2UsIlNob3dEaXNjbGFpbWVyIjp0cnVlLCJ1bml0IjoicHgifQ=='><\/div>"}],"metadata":{"primarytagid":"113002"},"issticky":false,"tags":[{"tag":"China","id":98302,"tagid":98302,"tx":"Location","txprefix":"location","txid":4030,"query":"location:China","classname":null},{"tag":"Earnings","id":112892,"tagid":112892,"tx":"Topic","txprefix":"topic","txid":4000,"query":"topic:Earnings","classname":null},{"tag":"Companies","id":113002,"tagid":113002,"tx":"Sector","txprefix":"sector","txid":4010,"query":"sector:Companies","classname":"blue-2"},{"tag":"US","id":119052,"tagid":119052,"tx":"Location","txprefix":"location","txid":4030,"query":"location:US","classname":null},{"tag":"Wynn Resorts","id":122732,"tagid":122732,"tx":"Company","txprefix":"company","txid":4050,"query":"company:\"Wynn Resorts\"","classname":null}],"uuidv3":"152e41e2-835e-3767-8ddc-c9cc54aebf2a","sortval":"0-0-01399052953"}],"srh":{"query":{"id":null,"str":"cameron","url":"cameron","obj":{"op":"AND","st":"cameron","tms":[{"txid":null,"pr":null,"tid":null,"t":"cameron"}]},"hash":"bb36feaac46d7aaab418138b578fd7e0"},"sort":"date","limit":10,"offset":0,"dispopts":[]},"resultsummarytext":"75 results","total":75,"filters":{"4000":{"id":4000,"name":"Topic","plural":"Topics","terms":{"1":{"tagid":"86032","freq":10,"type":"inresults","tag":"Economy","term":"topic:Economy","isprotected":0},"0":{"tagid":"113072","freq":33,"type":"inresults","tag":"World News","term":"topic:\"World News\"","isprotected":0}},"iscomplete":false,"summary":""},"4010":{"id":4010,"name":"Sector","plural":"Sectors","terms":{"1":{"tagid":"113112","freq":3,"type":"inresults","tag":"Banking","term":"sector:Banking","isprotected":0},"0":{"tagid":"113002","freq":28,"type":"inresults","tag":"Companies","term":"sector:Companies","isprotected":0}},"iscomplete":false,"summary":""},"4020":{"id":4020,"name":"Person","plural":"People","terms":[{"tagid":"88992","freq":17,"type":"inresults","tag":"David Cameron","term":"person:\"David Cameron\"","isprotected":0},{"tagid":"89492","freq":7,"type":"inresults","tag":"Ed Miliband","term":"person:\"Ed Miliband\"","isprotected":0}],"iscomplete":false,"summary":""},"4030":{"id":4030,"name":"Location","plural":"Locations","terms":{"1":{"tagid":"99002","freq":7,"type":"inresults","tag":"Syria","term":"location:Syria","isprotected":0},"0":{"tagid":"98232","freq":23,"type":"inresults","tag":"UK","term":"location:UK","isprotected":0}},"iscomplete":false,"summary":""},"4040":{"id":4040,"name":"Institution","plural":"Institutions","terms":[{"tagid":"100252","freq":2,"type":"inresults","tag":"European Commission","term":"institution:\"European Commission\"","isprotected":0},{"tagid":"100432","freq":1,"type":"inresults","tag":"NATO","term":"institution:NATO","isprotected":0}],"iscomplete":false,"summary":""},"4050":{"id":4050,"name":"Company","plural":"Companies","terms":{"1":{"tagid":"102332","freq":5,"type":"inresults","tag":"AstraZeneca","term":"company:AstraZeneca","isprotected":0},"0":{"tagid":"102192","freq":5,"type":"inresults","tag":"Pfizer","term":"company:Pfizer","isprotected":0}},"iscomplete":false,"summary":""}}}}]